Lourens T. Bloem

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs

Rick A. Vreman, Jacoline C. Bouvy, Lourens T. Bloem et al. · Clinical Pharmacology & Therapeutics · 2018 · 58 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +7

Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study

Francine Brinkhuis, Wim Goettsch, Aukje K. Mantel‐Teeuwisse et al. · BMJ · 2024 · 35 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +14

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies

Lourens T. Bloem, Rick A. Vreman, Niels Peeters et al. · Clinical and Translational Science · 2021 · 28 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +12

Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing

Chiel F Ebbelaar, Anne M.R. Schrader, Marijke van Dijk et al. · Modern Pathology · 2022 · 27 citations · Full text

Medicine, Molecular Genetics, Oncology +17

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs

Rick A. Vreman, Lourens T. Bloem, Stijn van Oirschot et al. · International Journal of Health Policy and Management · 2020 · 24 citations · Full text

Pharmacy, Health Policy, Pharmaceutical Policy +14